Ireland - English - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - levothyroxine sodium - tablet - 25 microgram(s) - thyroid hormones; levothyroxine sodium

Singapore - English - HSA (Health Sciences Authority)

merck pte. ltd. - levothyroxine sodium - tablet - 75 mcg - levothyroxine sodium 75 mcg

Singapore - English - HSA (Health Sciences Authority)

merck pte. ltd. - levothyroxine sodium - tablet - 50 mcg - levothyroxine sodium 50 mcg

Singapore - English - HSA (Health Sciences Authority)

merck pte. ltd. - levothyroxine sodium - tablet - 100 mcg - levothyroxine sodium 100 mcg

Singapore - English - HSA (Health Sciences Authority)

merck pte. ltd. - levothyroxine sodium - tablet - 25 mcg - levothyroxine sodium 25 mcg

Canada - English - Health Canada

organon canada inc. - etonogestrel; ethinyl estradiol - ring (slow-release) - 11.4mg; 2.6mg - etonogestrel 11.4mg; ethinyl estradiol 2.6mg - contraceptives

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - gemfibrozil, quantity: 600 mg - tablet, film coated - excipient ingredients: methylcellulose; hypromellose; macrogol 8000; hyprolose; magnesium stearate; colloidal anhydrous silica; croscarmellose sodium; titanium dioxide - pharmacor gemfibrozil 600 is indicated as an adjunct to diet and other therapeutic measures for: severe hypertriglyceridaemia (type iv and v) in persons who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. dyslipidaemia associated with diabetes. reduction of risk of coronary heart disease in patients with type iia and iib hypercholesterolaemia. because of potential toxicity such as malignancy, gallbladder disease, abdominal pain leading to appendectomy and other abdominal surgeries, an increased incidence in noncoronary mortality, and the 29% increase in all-cause mortality seen with chemically and pharmacologically related drug, clofibrate, the potential benefits of gemibrozil in treating type iia patients with elevations of ldl-cholesterol only is not likely to outweigh the risks. in a subgroup analysis of patients in the helsinki heart study with above median hdl-cholesterol values at baseline (greater than 1.2mmol/l), the incidence of serious coronary events was similar for gemfibrozil and placebo subgroups. note: pharmacor gemfibrozil 600 is indicated when exercise, weight loss and specific dietary or other non-drug measures such as limiting alcohol intake have failed. other medical disorders such as hypothyroidism and diabetes should be controlled as much as possible. periodic determination of serum lipids should be obtained during treatment with pharmacor gemfibrozil 600. the drug should be withdrawn or additional therapy instituted if the lipid response is deemed inadequate after three months.,pharmacor gemfibrozil 600 is indicated as an adjunct to diet and other therapeutic measures for: severe hypertriglyceridaemia (type iv and v) in persons who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. dyslipidaemia associated with diabetes. reduction of risk of coronary heart disease in patients with type iia and iib hypercholesterolaemia. because of potential toxicity such as malignancy, gallbladder disease, abdominal pain leading to appendectomy and other abdominal surgeries, an increased incidence in noncoronary mortality, and the 29% increase in all-cause mortality seen with chemically and pharmacologically related drug, clofibrate, the potential benefits of gemfibrozil in treating type iia patients with elevations of ldl-cholesterol only is not likely to outweigh the risks. in a subgroup analysis of patients in the helsinki heart study with above median hdl-cholesterol values at baseline (greater than 1.2mmol/l), the incidence of serious coronary events was similar for gemfibrozil and placebo subgroups. note: pharmacor gemfibrozil 600 is indicated when exercise, weight loss and specific dietary or other non-drug measures such as limiting alcohol intake have failed. other medical disorders such as hypothyroidism and diabetes should be controlled as much as possible. periodic determination of serum lipids should be obtained during treatment with pharmacor gemfibrozil 600. the drug should be withdrawn or additional therapy instituted if the lipid response is deemed inadequate after three months.

Israel - English - Ministry of Health

raz pharmaceutics ltd, israel - levothyroxine sodium - solution for injection/ concentrate for solution for infusion - levothyroxine sodium 0.2 mg / 1 ml - levothyroxine sodium - •myxedema coma•replacement or supplemental therapy in congenital or acquired hypothyroidism of any etiology

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - phenindione -

Israel - English - Ministry of Health

merck serono ltd - levothyroxine sodium - tablets - levothyroxine sodium 50 mcg - levothyroxine sodium - levothyroxine sodium - euthyrox 25 - 200 microgram :- treatment of benign euthyroid goitre.- prophylaxis of relapse after surgery for euthyroid goitre, depending on the post - operative hormone status.- substitution therapy in hypothyroidism.- suppression therapy in thyroid cancer.euthyrox 25 - 100 microgram :- concomitant supplementation during anti-thyroid drug treatment of hyperthyroidism.euthyrox 100/150/200 microgram :- diagnostic use for thyroid suppression testing.